readthroughSign in
Nov 12, 2026Quarterly update

Avalyn starts Phase 1 trial of dual-combination inhaled drug AP03

The biotech reported Q3 2026 results, with topline data across all three pulmonary fibrosis programs expected in 2027 and cash extending into 2029.

Avalyn Pharma reported third quarter 2026 results on November 12, 2026, highlighting progress across its three inhaled pulmonary fibrosis programs. The company initiated a Phase 1 trial of AP03, an inhaled combination of pirfenidone and nintedanib, structured as a randomized, double-blinded, placebo controlled, single-center study designed to assess safety, tolerability, and pharmacokinetics in healthy volunteers.1 The trial is expected to enroll at least 32 participants across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, with the SAD cohort beginning at a combination dose of 50 mg pirfenidone plus 2 mg nintedanib.1 The study is cleared to proceed in Australia following Human Research Ethics Committee and institutional approval, with notification to the Therapeutic Goods Administration under the Clinical Trial Notification pathway, registered as ACTRN12626001341314.1 Results from this AP03 study are anticipated in the second half of 2027.1

For AP01, inhaled pirfenidone, results from the MIST Phase 2b trial in patients with progressive pulmonary fibrosis are anticipated in the second half of 2027.1 For AP02, inhaled nintedanib, the company published Phase 1 data in Respiratory Research showing lung-targeted delivery, higher lung exposure and lower systemic exposure versus oral nintedanib, and a generally well-tolerated profile with no serious adverse events across two Phase 1 studies.1 Results from the AURA Phase 2 trial of AP02 in IPF patients are anticipated in late 2027.1

On the balance sheet, Avalyn held $386.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which the company said is projected to fund operations into 2029.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.